Clinical trial
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
NCT01030861 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT01030861 |
|---|---|
| Title | Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" |
| Official title | AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Center for Research Resources (NCRR)… |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance |
| Intervention type | Drug |
| Interventions | Teplizumab, Placebo infusion |
| Enrollment | 76 |
| Start date | Aug 1, 2010 |
| Primary completion | Nov 1, 2018 |
| Completion | Jun 1, 2019 |
| First posted | Dec 14, 2009 |
| Last update posted | Aug 5, 2020 |
| Countries | Canada, Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: